Cargando…

von Willebrand factor, ADAMTS-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction

BACKGROUND: von Willebrand factor (VWF) multimers are cleaved by A disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS-13) into less active fragments. Thrombospondin 1 (TSP-1) competes with VWF’s cleavage site, protecting it from degradation. Low ADAMTS-13 and high...

Descripción completa

Detalles Bibliográficos
Autores principales: Warlo, Ellen M.K., Kalstad, Are A., Myhre, Peder L., Solheim, Svein, Arnesen, Harald, Tveit, Arnljot, Holme, Pål Andre, Seljeflot, Ingebjørg, Bratseth, Vibeke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225923/
https://www.ncbi.nlm.nih.gov/pubmed/37255854
http://dx.doi.org/10.1016/j.rpth.2023.100164
_version_ 1785050477535166464
author Warlo, Ellen M.K.
Kalstad, Are A.
Myhre, Peder L.
Solheim, Svein
Arnesen, Harald
Tveit, Arnljot
Holme, Pål Andre
Seljeflot, Ingebjørg
Bratseth, Vibeke
author_facet Warlo, Ellen M.K.
Kalstad, Are A.
Myhre, Peder L.
Solheim, Svein
Arnesen, Harald
Tveit, Arnljot
Holme, Pål Andre
Seljeflot, Ingebjørg
Bratseth, Vibeke
author_sort Warlo, Ellen M.K.
collection PubMed
description BACKGROUND: von Willebrand factor (VWF) multimers are cleaved by A disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS-13) into less active fragments. Thrombospondin 1 (TSP-1) competes with VWF’s cleavage site, protecting it from degradation. Low ADAMTS-13 and high VWF have been associated with cardiovascular disease and atrial fibrillation (AF). OBJECTIVES: We aimed to investigate whether VWF, ADAMTS-13, and TSP-1 are associated with clinical outcome. METHODS: Elderly patients with a recent myocardial infarction (MI) (n = 1027) were followed for 2 years. Blood was collected 2 to 8 weeks after the MI for ADAMTS-13, VWF, and TSP-1 measures. The primary endpoints (major adverse cardiovascular events; n = 210) included the first event of MI, stroke, heart failure hospitalization, coronary revascularization, and all-cause death. Total mortality was also registered (n = 56). The secondary endpoint was new-onset AF (n = 43). RESULTS: Concentrations of VWF, ADAMTS-13, and TSP-1 did not intercorrelate. The risk of major adverse cardiovascular events was altered in patients with VWF ≥ median (hazard ratio [HR], 1.4; 95% CI, 1.0-1.8; P = .03) and ADAMTS-13 ≥ median (HR, 0.7; 95% CI, 0.5-0.9; P = .02); however, it was not significant in adjusted models. VWF and ADAMTS-13 were significantly associated with total mortality, with a HR of 2.7 (95% CI, 1.6-4.6; P < .001) for VWF (Q4 vs. Q1-Q3) and HR of 0.3 (95% CI, 0.2-0.5; P < .001) for ADAMTS-13 (Q2-4 vs. Q1). The associations persisted in multivariable analysis, but the significance disappeared for VWF after correcting for high-sensitivity C-reactive protein. The risk of new-onset AF was lower in patients with VWF ≥ median (HR, 0.5; 95% CI, 0.3-1.0; P = .04]), and this was still significant after adjustments. CONCLUSION: Although low ADAMTS-13 predicted death, the cardiovascular risk associated with VWF and ADAMTS-13 was weaker than previously reported. Low VWF is associated with new-onset AF and needs further research.
format Online
Article
Text
id pubmed-10225923
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-102259232023-05-30 von Willebrand factor, ADAMTS-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction Warlo, Ellen M.K. Kalstad, Are A. Myhre, Peder L. Solheim, Svein Arnesen, Harald Tveit, Arnljot Holme, Pål Andre Seljeflot, Ingebjørg Bratseth, Vibeke Res Pract Thromb Haemost Original Article BACKGROUND: von Willebrand factor (VWF) multimers are cleaved by A disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS-13) into less active fragments. Thrombospondin 1 (TSP-1) competes with VWF’s cleavage site, protecting it from degradation. Low ADAMTS-13 and high VWF have been associated with cardiovascular disease and atrial fibrillation (AF). OBJECTIVES: We aimed to investigate whether VWF, ADAMTS-13, and TSP-1 are associated with clinical outcome. METHODS: Elderly patients with a recent myocardial infarction (MI) (n = 1027) were followed for 2 years. Blood was collected 2 to 8 weeks after the MI for ADAMTS-13, VWF, and TSP-1 measures. The primary endpoints (major adverse cardiovascular events; n = 210) included the first event of MI, stroke, heart failure hospitalization, coronary revascularization, and all-cause death. Total mortality was also registered (n = 56). The secondary endpoint was new-onset AF (n = 43). RESULTS: Concentrations of VWF, ADAMTS-13, and TSP-1 did not intercorrelate. The risk of major adverse cardiovascular events was altered in patients with VWF ≥ median (hazard ratio [HR], 1.4; 95% CI, 1.0-1.8; P = .03) and ADAMTS-13 ≥ median (HR, 0.7; 95% CI, 0.5-0.9; P = .02); however, it was not significant in adjusted models. VWF and ADAMTS-13 were significantly associated with total mortality, with a HR of 2.7 (95% CI, 1.6-4.6; P < .001) for VWF (Q4 vs. Q1-Q3) and HR of 0.3 (95% CI, 0.2-0.5; P < .001) for ADAMTS-13 (Q2-4 vs. Q1). The associations persisted in multivariable analysis, but the significance disappeared for VWF after correcting for high-sensitivity C-reactive protein. The risk of new-onset AF was lower in patients with VWF ≥ median (HR, 0.5; 95% CI, 0.3-1.0; P = .04]), and this was still significant after adjustments. CONCLUSION: Although low ADAMTS-13 predicted death, the cardiovascular risk associated with VWF and ADAMTS-13 was weaker than previously reported. Low VWF is associated with new-onset AF and needs further research. Elsevier 2023-04-23 /pmc/articles/PMC10225923/ /pubmed/37255854 http://dx.doi.org/10.1016/j.rpth.2023.100164 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Article
Warlo, Ellen M.K.
Kalstad, Are A.
Myhre, Peder L.
Solheim, Svein
Arnesen, Harald
Tveit, Arnljot
Holme, Pål Andre
Seljeflot, Ingebjørg
Bratseth, Vibeke
von Willebrand factor, ADAMTS-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction
title von Willebrand factor, ADAMTS-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction
title_full von Willebrand factor, ADAMTS-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction
title_fullStr von Willebrand factor, ADAMTS-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction
title_full_unstemmed von Willebrand factor, ADAMTS-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction
title_short von Willebrand factor, ADAMTS-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction
title_sort von willebrand factor, adamts-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225923/
https://www.ncbi.nlm.nih.gov/pubmed/37255854
http://dx.doi.org/10.1016/j.rpth.2023.100164
work_keys_str_mv AT warloellenmk vonwillebrandfactoradamts13andthrombospondin1inrelationtoclinicaloutcomesinelderlypatientswitharecentmyocardialinfarction
AT kalstadarea vonwillebrandfactoradamts13andthrombospondin1inrelationtoclinicaloutcomesinelderlypatientswitharecentmyocardialinfarction
AT myhrepederl vonwillebrandfactoradamts13andthrombospondin1inrelationtoclinicaloutcomesinelderlypatientswitharecentmyocardialinfarction
AT solheimsvein vonwillebrandfactoradamts13andthrombospondin1inrelationtoclinicaloutcomesinelderlypatientswitharecentmyocardialinfarction
AT arnesenharald vonwillebrandfactoradamts13andthrombospondin1inrelationtoclinicaloutcomesinelderlypatientswitharecentmyocardialinfarction
AT tveitarnljot vonwillebrandfactoradamts13andthrombospondin1inrelationtoclinicaloutcomesinelderlypatientswitharecentmyocardialinfarction
AT holmepalandre vonwillebrandfactoradamts13andthrombospondin1inrelationtoclinicaloutcomesinelderlypatientswitharecentmyocardialinfarction
AT seljeflotingebjørg vonwillebrandfactoradamts13andthrombospondin1inrelationtoclinicaloutcomesinelderlypatientswitharecentmyocardialinfarction
AT bratsethvibeke vonwillebrandfactoradamts13andthrombospondin1inrelationtoclinicaloutcomesinelderlypatientswitharecentmyocardialinfarction